spacer
home > > spring 2018 > data diligence
PUBLICATIONS


Data Diligence

Following headlines covering the Facebook and Cambridge Analytica saga, awareness of not only privacy issues, but also the underlying value of data held by corporations and how they are processed has heightened. One area highlighted in this article is how data collected by pharmaceutical companies is underutilised to inform data-driven decisionmaking across the board.

Unlocking Marketing Data

Traditionally, supply chain design and management has focused solely on sourcing products as well as distribution. However, many pharma companies’ supply chains are based on outdated legacy models where high demand and margins were once the norm. With the emergence of generic products, expiring patents, over-the-counter products, and an increased focus on emerging markets to deliver competitiveness, pharma companies need to design and introduce new supply chain models that require new systems, processes, and metrics to be implemented. The definition of supply chain management has broadened over the years, and, in the data-centric world people live in today, supply chain decision makers have begun realising the importance of regulatory, market, and healthcare professional client data, in designing more competitive supply chain models.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Kieran Bourke at MAXX Design is focused on the development of marketing solutions for pharma companies and has previously worked closely with GSK across its consumer marketing portfolio, helping them to innovate around the rapid rise of mobile marketing. He was previously a spokesperson for the Institute of Practitioners in Advertising.
spacer
Kieran Bourke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sense Accelerates Instrument-Free Molecular Diagnostic Test for COVID-19

April 1, 2020 – Sense Biodetection Limited (Sense) has today announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement